Type of information: IPO
Company: Allogene Therapeutics (USA - CA)
Amount: $372.6 million
Funding type: IPO
• On October 15, 2018, Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $18.00 per share. Including the option exercise, the gross proceeds to Allogene Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were $372.6 million.
• On October 10, 2018, Allogene Therapeutics announced the pricing of its initial public offering of 18,000,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Allogene Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $324.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on October 11, 2018 under the symbol "ALLO." The offering is expected to close on October 15, 2018, subject to customary closing conditions. In addition, Allogene Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of common stock.
- • On September 14, 2018, Allogene Therapeutics announced it has filed an S-1 registration statement with the Securities and Exchange Commission (“SEC”) relating to a proposed offering of its common stock. All shares of common stock to be sold in the offering will be offered by Allogene. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Allogene has applied to list its stock for trading on the NASDAQ under the symbol “ALLO.”
- Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC are acting as the joint book-running managers for the proposed offering.
Therapeutic area: Cancer - Oncology